GIST
Conditions
Brief summary
This is a cross-sectional cohort study of metastatic GastroIntestinal Stromal Tumor (GIST) patients on imatinib for ≥ 10 years included in EORTC trial 62005-STBSG entitled Phase 3 randomized, intergroup, international tiral assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) expressing the KIT receptor tyrosine kinase (CD117) - NCT00685828. With this study, the aim is to identify patient characteristics, tumour characteristics, treatment factors and quality of life outcomes associated with prolonged treatment with imatinib and/or prolonged survival. This observational study will further help to put in place a questionnaire to evaluate patients quality of life with prolonged imatinib treatment, that will then be used in a prospective study.
Interventions
OTHERNo intervention
No intervention
Sponsors
European Organisation for Research and Treatment of Cancer - EORTC
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
28 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients included in the EORTC 62005 trial: Adult patients with metastasized GIST * Patients who have been treated with imatinib for ten years or longer * For the identified patients who are still alive: 1. Able to read and answer questionnaires 2. Able to provide written informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patient characteristics | At time of registration | Age at time of randomization, gender, medical history and previous treatment(s) |
| Tumour characteristics | At time of registration | Stage of the disease, tumor grade, tumor location and molecular features of primary tumor |
| Duration of imatinib treatment | At time of registration | Time on imatinib treatment from start untill definitive discontinuation of imatinib treatment |
| Health releated quality of life | At time of registration | QLQ-C30 |
| Overall survival | At time of registration | From time of randomization to the date of death, whatever the cause |
Outcome results
None listed